National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells
Immune effector cells (IECs) offer a new approach to address unmet medical needs, including malignancies, autoimmune diseases, and opportunistic infections.1,2 This family of biologics, also known as cellular immunotherapies, includes chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), and genetically modified T cell receptors (TCRs).3 Currently, six CAR T products have been approved by the U.S. Food and Drug Administration (FDA) for various hematological malignancies.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Magdi Elsallab, Florence Bourgeois, Marcela V. Maus Source Type: research
More News: Autoimmune Disease | Biology | Cancer & Oncology | Food and Drug Administration (FDA) | Genetics | Hematology | Immunotherapy | Transplants